CTNI-37. EFFICACY OF ONC201 IN PATIENTS WITH ONC201 FOR RECURRENT H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA

H3 K27M-mutant diffuse midline gliomas (DMG) have a dismal prognosis. We report an integrated analysis for ONC201, a DRD2 antagonist and ClpP agonist, in patients with recurrent H3 K27M DMG administered as monotherapy in 3 clinical studies (NCT03295396, n=20; NCT02525692, n=6; or expanded access, n=...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Arrillaga-Romany, Isabel, Kurz, Sylvia, Tarapore, Rohinton S, Sumrall, Ashley, Butowski, Nicholas, Harrison, Rebecca, de Groot, John, Chi, Andrew, Shonka, Nicole, Umemura, Yoshie, Odia, Yazmin, Mehta, Minesh, Nghiemphu, Phioanh, Cloughesy, Timothy, Taylor, Lynne, Graber, Jerome, Kilburn, Lindsay, Dixit, Karan, Lu, Guangrong, Allen, Joshua, Batchelor, Tracy, Lassman, Andrew, Wen, Patrick
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Clinical Trials: Non-Immunologic
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651099/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.204
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados